Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma
- 5 January 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 119 (1), 161-169
- https://doi.org/10.1182/blood-2011-07-368472
Abstract
Dickkopf-1 (DKK1), broadly expressed in myeloma cells but highly restricted in normal tissues, together with its functional roles as an osteoblast formation inhibitor, may be an ideal target for immunotherapy in myeloma. Our previous studies have shown that DKK1 (peptide)–specific CTLs can effectively lyse primary myeloma cells in vitro. The goal of this study was to examine whether DKK1 can be used as a tumor vaccine to elicit DKK1-specific immunity that can control myeloma growth or even eradicate established myeloma in vivo. We used DKK1-DNA vaccine in the murine MOPC-21 myeloma model, and the results clearly showed that active vaccination using the DKK1 vaccine not only was able to protect mice from developing myeloma, but it was also therapeutic against established myeloma. Furthermore, the addition of CpG as an adjuvant, or injection of B7H1-blocking or OX40-agonist Abs, further enhanced the therapeutic effects of the vaccine. Mechanistic studies revealed that DKK1 vaccine elicited a strong DKK1- and tumor-specific CD4+ and CD8+ immune responses, and treatment with B7H1 or OX40 Abs significantly reduced the numbers of IL-10–expressing and Foxp3+ regulatory T cells in vaccinated mice. Thus, our studies provide strong rationale for targeting DKK1 for immunotherapy of myeloma patients.This publication has 50 references indexed in Scilit:
- Strategies for Cancer Vaccine DevelopmentJournal of Biomedicine and Biotechnology, 2010
- B cell depletion reduces the development of atherosclerosis in miceThe Journal of Experimental Medicine, 2010
- Myeloma cell line–derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myelomaBlood, 2009
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaBlood, 2009
- Roles of Idiotype-Specific T Cells in Myeloma Cell Growth and Survival: Th1 and CTL Cells Are Tumoricidal while Th2 Cells Promote Tumor GrowthCancer Research, 2008
- Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaBlood, 2007
- Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMTBlood, 2007
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivoBlood, 2006
- Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40Nature Reviews Immunology, 2004
- Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2Science, 2002